Skip to main content
OpenTrials
Completed

NCT Number: NCT07366372

Efficacy of Taurolidine Containing Lock Solution for Prevention of Central Venous Catheter Infection in ICU Patients

This study aimed to assess effectiveness of a taurolidine based lock solution in preventing the infections of central venous catheter (CVC) in intensive care unit (ICU) cases.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Taurolidine Central Venous Catheter Infection Intensive Care Unit Lock Solution Prevention

Age range

21 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Tanta University

Tanta, El-Gharbia, 31527, Egypt

About this study

The central venous catheter (CVC) is highly frequent in the intensive care unit (ICU), with an average use rate between 32% and 80% among adult ICU patients. The utilization of CVC in ICUs has escalated over the past decade, accompanied by a corresponding increase in problems related to their usage.

Taurolidine is a nontoxic substance having antibacterial impacts counter to mutually gram-positive and -negative bacteria, additionally to fungus. It decreases biofilm development and doesn't develop resistance to antibiotics, since it serves as an antiseptic rather than an antibiotic Consequently, it may function as a locking mechanism.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Age > 21 years.
  • Both genders.
  • Patients admitted to the intensive care unit (ICU) requiring central venous catheter insertion.

Exclusion criteria

  • Cases with active infections, hemorrhage or bleeding disorders, infections within insertion place.
  • History of allergy to taurolidine, tigecycline, heparin, and citrate.

Treatment and study plan

Saline

Drug

Central venous catheters (CVCs) were locked with 2ml saline as a control group.

Tigecycline and heparin

Drug

Central venous catheters (CVCs) were locked with 2ml of a solution comprising tigecycline 5mg/ml and heparin 500 IU/ml.

Taurolidine-citrate-heparin

Drug

Central venous catheters (CVCs) were locked with 2ml of a solution containing taurolidine-citrate-heparin (1.35% taurolidine, 4% citrate, and 500 IU/ml heparin).

Primary outcomes

  1. Positive bacterial growth

    Time frame: 30 days after the procedure

    Positive bacterial growth of a swab was recorded.

Secondary outcomes

  1. Assessment of catheter-related bloodstream infection

    Time frame: 30 days after the procedure

    Assessment of catheter-related bloodstream infection was recorded.

  2. Assessment of central venous catheter infection

    Time frame: 30 days after the procedure

    Assessment of central venous catheter (CVC) infection was recorded.

  3. Lenght of intensive care unit stay

    Time frame: 30 days after the procedure

    Lenght of intensive care unit (ICU) stay was recorded.

  4. Incidence of mortality

    Time frame: 30 days after the procedure

    Incidence of mortality was recorded.

Sponsors and collaborators

Lead sponsor

Tanta University

Other

Registry information

Official study title

The Efficacy of Taurolidine Containing Lock Solution for Prevention of Central Venous Catheter Infection in ICU Patients

Important dates

Study start
2023
Primary completion
2024
Study completion
2024
First posted
Jan 26, 2026
Registry last updated
Jan 26, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.